Updated NETs Clinical Trials

• Beyond Psychological Distress: Implementation of a Dyadic Behavioral Intervention Targeting Neuroendocrine and mRNA Translational Pathways in Late-Stage Breast Cancer

  Conditions: CASA Intervention; Usual Care Interventions: Behavioral: The Caregivers-Patients Support to Cope with Advanced Cancer (CASA) is a five-session, manualized, meaning-centered psychotherapy developed for Puerto Rican patients and caregivers coping with advance; Behavioral: Control Condition. Includes CBT as the primary treatment approach for cancer patients and it is considered the usual care approach in these clinics, as well as one of the primar Sponsors: Ponce Medical School Foundation, Inc. Not yet recruiting

• Acute Effects of HIIT and MICT on Catestatin Dynamics in Young Males

  Conditions: Healthy Volunteers; Exercise Physiology; Autonomic Nervous System Regulation Interventions: Other: High-Intensity Interval Exercise; Other: Moderate-Intensity Continuous Exercise Sponsors: Firat University; The Scientific and Technological Research Council of Turkey Completed

• Optimizing Risk Assessment Through cfDNA in Pancreatic Neuroendocrine Tumors for Clinical Evaluation

  Conditions: Pancreatic Neuroendocrine Tumor Interventions: Other: cfDNA molecular profiling Sponsors: Massimo Falconi Active, not recruiting

• Thyroid Health Outcomes Registry for Surgery

  Conditions: Thyroid Diseases; Thyroid Neoplasms; Thyroid Cancer; Thyroid Nodules; Goiter; Medullary Thyroid Carcinoma; Thyroid Surgery for Benign Disease; Real-World Data; Adrenal Gland Neoplasms; Adrenal Cancer; Endocrine Surgery; Neck Dissection Sponsors: Pirogov Russian National Research Medical University Not yet recruiting

• China Treatment Trial for Tumor in Sellar Region With Unruptured Intracranial Aneurysm

  Conditions: Unruptured Intracranial Aneurysms; Pituitary Neuroendocrine Tumor; Craniopharyngioma; Meningioma; Germinoma; Rathke Cleft Cysts; Chordoma; Optic Pathway Glioma; Hypothalamic Neoplasms Interventions: Procedure: Tumor resection followed by aneurysm treatment; Procedure: Aneurysm treatment followed by tumor resection; Other: Observation Sponsors: Cheng sen; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; West China Hospital; Xijing Hospital; Shandong Provincial Hospital; The First Affiliated Hospital of Anhui Medical University; First Affiliated Hospital of Chongqing Medical University; Shengjing Hospital; Lanzhou University Second Hospital; The First Hospital of Jilin University; People's Hospital of Xinjiang Uygur Autonomous Region; Guangdong Provincial Hospital of Traditional Chinese Medicine; Huashan Hospital; Jinling Hospital, China Not yet recruiting

• CyberKnife Radiotherapy for the Treatment of Schwannomas

  Conditions: Schwannoma, Vestibular Sponsors: Hartmann Oncology Radiotherapy Group, France; Institut Rafael Completed

• Tarlatamab in Recurrent Gynecological Neuroendocrine Carcinomas: A Phase II Proof-of-concept Study

  Conditions: Diagnosis of Neuro-endocrine Carcinoma of the Gynecological Tract Interventions: Drug: Tarlatamab treatment Sponsors: University Hospital, Strasbourg, France Not yet recruiting

• Comparison of an Initial Active Follow-up and Therapeutic Care on Functional Outcome and Quality of Life in Patients With Head and Neck Paragangliomas

  Conditions: Paragangliomas Interventions: Other: Active follow-up; Procedure: Surgery; Radiation: Radiation Sponsors: Hospices Civils de Lyon Not yet recruiting

• A Study of Armored CAR T Cells in People With Cancer

  Conditions: Neuroendocrine Cancer; Small Cell Lung Cancer; Small Cell Lung Cancer ( SCLC ) Interventions: Drug: DLL3-SAVVYZ-IL18 CAR T cell Sponsors: Memorial Sloan Kettering Cancer Center Recruiting

• Real-World Study of the Safety and Efficacy of Surufatinib in the Treatment of Neuroendocrine Tumors

  Conditions: Neuroendocrine (NE) Tumors Interventions: Drug: Surufatinib Administration Sponsors: Yefeng Not yet recruiting

• Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid Tumors

  Conditions: Cancer; Pediatric Cancer Interventions: Drug: Zanzalintinib Sponsors: Exelixis Not yet recruiting

• STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)

  Conditions: Adrenocortical Carcinoma; Pheochromocytoma; Paraganglioma Interventions: Drug: Ivonescimab Sponsors: M.D. Anderson Cancer Center; Summit Therapeutics Not yet recruiting

• A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC

  Conditions: Advanced Extrapulmonary Neuroendocrine Carcinoma Interventions: Drug: LBL-024 for Injection; Drug: Etoposide injection; Drug: Cisplatin injection; Drug: Carboplatin injection; Drug: LBL-024 placebo for injection Sponsors: Nanjing Leads Biolabs Co.,Ltd; Peking University Cancer Hospital & Institute Not yet recruiting

• DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers

  Conditions: Small Cell Lung Cancer; Large Cell Neuroendocrine Lung Carcinoma; Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology; Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology Interventions: Drug: Obrixtamig; Drug: ZL-1310; Drug: Atezolizumab Sponsors: Boehringer Ingelheim; Zai Lab Not yet recruiting

• Autonomic and Peripheral Neurochemical Responses to Maximal Rowing Exercise

  Conditions: Healhty Interventions: Other: Maximal 6,000-m rowing ergometer test Sponsors: Poznan University of Physical Education; Nicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz Completed

• Sacituzumab Tirumotecan in Pts w/ NEPC After Progression on Prior Chemotherapy

  Conditions: Prostate Cancer; Neuroendocrine Prostate Cancer (NEPC) Interventions: Drug: Sacituzumab Tirumotecan Sponsors: Virginia Commonwealth University; Merck Sharp & Dohme LLC Not yet recruiting

• A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the Lung

  Conditions: Large Cell Neuroendocrine Carcinoma of the Lung Interventions: Drug: Obrixtamig Sponsors: Technische Universität Dresden Not yet recruiting

• DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  Conditions: Extrapulmonary Neuroendocrine Cancer (epNEC) Interventions: Drug: Obrixtamig; Drug: Carboplatin; Drug: Etoposide; Device: Ventana DLL3 RxDx assay Sponsors: Boehringer Ingelheim Recruiting

• Breathwork and Stress: Investigating the Mechanisms of Action and Effectiveness of Breathing Interventions in Modulating the Psychophysiological Response to Acute Stress Test

  Conditions: Healthy Adult Participants; Acute Stress Reaction; Stress Biomarkers; Healthy Interventions: Behavioral: Coherent Breathing (6 bpm); Behavioral: Sham Breathing (15 bpm) Sponsors: Medical University of Bialystok Active, not recruiting

• Adults With Constipation

  Conditions: Constipation Interventions: Dietary Supplement: Probiotics; Dietary Supplement: Placebo Sponsors: Wecare Probiotics Co., Ltd. Recruiting

• Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease

  Conditions: Extensive-Stage Small Cell Lung Cancer; Extrapulmonary Neuroendocrine Carcinoma; Recurrent or Refractory; Solid Tumors Interventions: Drug: Autologous B7-H3 CAR T; Drug: Cyclophosphamide; Drug: Fludarabine Sponsors: National Cancer Institute (NCI) Not yet recruiting

• Mind-Body Group Interventions for Psychological Distress in Young Breast Cancer Survivors

  Conditions: Breast Cancer Interventions: Behavioral: Breath-Body-Mind (BBM); Behavioral: Survivorship education program (SEP) Sponsors: University of Alabama at Birmingham Not yet recruiting

• A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)

  Conditions: Small Cell Lung Cancer (SCLC ); Extrapulmonary Neuroendocrine Carcinoma (EP-NEC); Gastroenteropancreatic NEC (GEP NEC); Neuroendocrine Prostate Cancer (NEPC) Interventions: Biological: ML261 Sponsors: Moonlight Bio, Inc Recruiting

• ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1

  Conditions: Merkel Cell Carcinoma; Merkel Cell Carcinoma, Stage III; Merkel Cell Carcinoma, Stage IV Interventions: Drug: ASTX727 + retifanlimab Sponsors: University of Wisconsin, Madison Not yet recruiting

• Assessment of Patient Experience With Auto-Captioning Glasses in NF2-Related-Schwannomatosis

  Conditions: NF2-related Schwannomatosis Interventions: Device: Auto-captioning Glasses Sponsors: Massachusetts General Hospital Completed

• Endoscopic Management of Biliopancreatic Disease in the Lombardy Pancreas Units

  Conditions: Pancreatic Cancer; Biliopancreatic Diseases; Periampullary Neoplasms Sponsors: IRCCS San Raffaele Not yet recruiting

• TheraSphere Japan Pre-Market Study

  Conditions: Liver Neoplasms Interventions: Device: TheraSphere Y-90 glass microsphere Sponsors: Boston Scientific Corporation Recruiting

• Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment

  Conditions: Neuroendocrine Tumors Sponsors: Ipsen Recruiting

• Superb Microvascular Imaging (SMI) and Two-Dimensional Endoscopic Ultrasound Guided Shear Wave Elastography (2D-SWE-EUS) in Differential Diagnosis of Pancreatic Adenocarcinoma (PA) From Other Pancreatic Solid Lesions (PSLs) and Pancreatic neuroendocrinE Tumors (pNETs) Malignancy

  Conditions: Pancreas Adenocarcinoma (MSI-H); Pancreatic Neuroendocrine Tumors (pNET) Interventions: Device: SMI and 2D-SWE modes Sponsors: GCS Ramsay Santé pour l'Enseignement et la Recherche Recruiting

• Neuroendocrine Carcinomas: Patient Journey And Treatment Outcomes In Latin America

  Conditions: Neuroendocrine Carcinomas; Lung Neuroendocrine Carcinoma Interventions: Other: Observational study Sponsors: Latin American Cooperative Oncology Group; Boehringer Ingelheim; Grupo Argentino de Investigación Clínica en Oncología; Grupo de Estudios Clínicos Oncológicos Peruano Recruiting

• Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS)

  Conditions: Polycystic Ovarian Syndrome in Adolescent Females; Obesity (Disorder) Interventions: Drug: GLP-1 Receptor Agonists Sponsors: Nemours Children's Clinic Recruiting

• Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

  Conditions: GEP-NET; Gastroenteropancreatic Neuroendocrine Tumor; Gastroenteropancreatic Neuroendocrine Tumor Disease; Neuroendocrine Tumors; Carcinoid; Carcinoid Tumor; Pancreatic NET; Solid Tumor; Somatostatin Receptor Interventions: Drug: RYZ401 Sponsors: RayzeBio, Inc. Recruiting

• Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

  Conditions: Carcinoid Syndrome; Carcinoid; Carcinoid Tumor; Carcinoid Tumor of Ileum; Carcinoid Tumor of Cecum; Carcinoid Tumor of Liver; Carcinoid Tumor of Pancreas; Carcinoid Syndrome Diarrhea; Carcinoid Intestine Tumor Interventions: Drug: Paltusotine; Drug: Placebo Sponsors: Crinetics Pharmaceuticals Inc. Recruiting

• Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

  Conditions: Small Cell Lung Cancer Metastatic or Locally Advanced; Neuroendocrine Cancer; Metastatic Neuroendocrine Prostate Cancer; Metastatic Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma; Metastatic Advanced Merkel Cell Carcinoma; Locally Advanced Large Cell Neuroendocrine Carcinoma of the Lung; Locally Advanced Extrapulmonary Neuroendocrine Carcinoma; Locally Advanced Neuroendocrine Prostate Cancer; Locally Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine; Locally Advanced Merkel Cell Carcinoma; Metastatic Large Cell Neuroendocrine Carcinoma of the Lung Interventions: Drug: BL-M14D1 Sponsors: SystImmune Inc. Recruiting

• Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab

  Conditions: Advanced Neuroendocrine Carcinomas of The Digestive System; Advanced Neuroendocrine Carcinomas Unknown Primary Origin Interventions: Drug: Tarlatamab; Drug: standard of care second-line chemotherapy (FOLFIRI) Sponsors: Grupo Espanol de Tumores Neuroendocrinos; Amgen Terminated

• Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)

  Conditions: Metastatic/Locally Advanced Small-Cell Lung Cancer; Metastatic/Locally Advanced Poorly Differentiated NEC Interventions: Drug: Tarlatamab Sponsors: Gustave Roussy, Cancer Campus, Grand Paris; Amgen Recruiting

• Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

  Conditions: Small Cell Lung Carcinoma; Large Cell Neuroendocrine Carcinoma of the Lung; Neuroendocrine Prostate Cancer; Gastroenteropancreatic Neuroendocrine Carcinoma; Non-prostate Extrapulmonary Neuroendocrine Carcinoma; Cervical Neuroendocrine Carcinoma; Thymic Neuroendocrine Carcinoma; Genitourinary Neuroendocrine Carcinoma; Unknown Primary Neuroendocrine Carcinomas; Merkel Cell Carcinoma; Medullary Thyroid Carcinoma Interventions: Drug: 225Ac-ETN029; Drug: 111In-ETN029 Sponsors: Novartis Pharmaceuticals Recruiting

• Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

  Conditions: Pancreatic Neuroendocrine Tumor (pNET); Extra-Pancreatic Neuroendocrine Tumor (epNET) Interventions: Drug: Zanzalintinib; Drug: Everolimus Sponsors: Exelixis Recruiting

• Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors

  Conditions: Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs) Interventions: Drug: 177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 16 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm.; Drug: 177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 8 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm.; Drug: Amino acid solution; Drug: Lanreotide (Autogel formulation) or Octreotide LAR Sponsors: Grupo Espanol de Tumores Neuroendocrinos; Grupo Español de Tumores Neuroendocrinos y Endocrinos (GETNE) Recruiting

• Adjuvant Chemotherapy for High Malignant Prostate Cancer

  Conditions: Prostate Cancer; Radiation Therapy; Chemotherapy; Gleason Score Interventions: Drug: Docetaxel Sponsors: Peking University First Hospital; Peking University Shenzhen Hospital Recruiting

• Tarlatamab for Advanced Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma (TAURUS)

  Conditions: Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma Interventions: Drug: Tarlatamab Sponsors: National Taiwan University Hospital; Amgen Recruiting

• Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms

  Conditions: DLL3-expressing Tumors; Advanced Tumors Interventions: Drug: Tarlatamab treatment Sponsors: Jonsson Comprehensive Cancer Center; Amgen Active, not recruiting

• Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

  Conditions: Somatostatin Receptor Positive (SSTR+); Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Interventions: Radiation: [177Lu]Lu-DOTA-TATE; Drug: Octreotide LAR Sponsors: Novartis Pharmaceuticals Recruiting

• Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies

  Conditions: Advanced Solid Tumor; Metastatic Solid Tumor; Refractory Solid Tumor; Cancer; Lung Cancer; Triple Negative Breast Cancer; Breast Neoplasms; Neuroendocrine Tumors; Neuroendocrine Carcinoma; RB1 Gene Mutation Interventions: Drug: CID-078 Monotherapy Sponsors: Circle Pharma Active, not recruiting

• NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations

  Conditions: Non-squamous Metastatic Non-Small-Cell Lung Carcinoma Sponsors: AstraZeneca Recruiting

• Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

  Conditions: Somatostatin Receptor Positive; NETs; Lymphoma; Solid Tumor; CNS Tumors; Rhabdomyosarcoma; Peripheral Primitive Neuroectodermal Tumor; GIST Interventions: Drug: Lutetium Lu 177-Edotreotide; Other: Amino Acid Solution Sponsors: ITM Solucin GmbH Recruiting

• A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

  Conditions: Carcinoma, Neuroendocrine; Tumor, Neuroendocrine; Tumors, Neuroendocrine; Neuroendocrine; Carcinoma; Small Cell; Receptors Interventions: Drug: Belinostat; Drug: Cisplatin; Drug: Etoposide Sponsors: National Cancer Institute (NCI) Recruiting

• A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma

  Conditions: Basal Ganglia Germinoma; Diabetes Insipidus; Germinoma; Pineal Region Germinoma; Suprasellar Germinoma; Thalamic Germinoma Interventions: Radiation: 3-Dimensional Conformal Proton Radiation Therapy; Radiation: 3-Dimensional Conformal Radiation Therapy; Procedure: Biospecimen Collection; Drug: Carboplatin; Drug: Etoposide; Procedure: Intensity-Modulated Proton Therapy; Radiation: Intensity-Modulated Radiation Therapy; Procedure: Lumbar Puncture; Procedure: Magnetic Resonance Imaging; Other: Questionnaire Administration; Procedure: Surgical Procedure Sponsors: Children's Oncology Group Recruiting

• Iconographic Registry of Pancreatobiliary Endoscopy Procedures

  Conditions: Pancreas Neoplasm; Cancer of Pancreas; Pancreatitis; Neuroendocrine Tumors Sponsors: IRCCS San Raffaele Recruiting

• Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours

  Conditions: Neuroendocrine Tumors Interventions: Drug: Cessation of somatostatin analogues; Drug: Continuation of somatostatin analogues Sponsors: Australasian Gastro-Intestinal Trials Group; Canadian Cancer Trials Group Recruiting